MA54089A - Anticorps anti-pd-1 humain et procédés d'utilisation associés - Google Patents

Anticorps anti-pd-1 humain et procédés d'utilisation associés

Info

Publication number
MA54089A
MA54089A MA054089A MA54089A MA54089A MA 54089 A MA54089 A MA 54089A MA 054089 A MA054089 A MA 054089A MA 54089 A MA54089 A MA 54089A MA 54089 A MA54089 A MA 54089A
Authority
MA
Morocco
Prior art keywords
antibodies
methods
human anti
human
Prior art date
Application number
MA054089A
Other languages
English (en)
Inventor
Thierry O Fischmann
Chakravarthy Nachu Narasimhan
Winifred W Prosise
Paul Reichert
Corey Strickland
Yongchao Su
Erika R Walsh
Xiaoyu Yang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA54089A publication Critical patent/MA54089A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054089A 2018-10-31 2019-10-28 Anticorps anti-pd-1 humain et procédés d'utilisation associés MA54089A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753615P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
MA54089A true MA54089A (fr) 2022-02-09

Family

ID=70463443

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054089A MA54089A (fr) 2018-10-31 2019-10-28 Anticorps anti-pd-1 humain et procédés d'utilisation associés

Country Status (11)

Country Link
US (1) US12576159B2 (fr)
EP (1) EP3873941A4 (fr)
JP (1) JP7475341B2 (fr)
KR (1) KR102876292B1 (fr)
CN (2) CN113015748B (fr)
AU (1) AU2019369222A1 (fr)
BR (1) BR112021008122A8 (fr)
CA (1) CA3116592A1 (fr)
MA (1) MA54089A (fr)
MX (1) MX2021004928A (fr)
WO (1) WO2020092233A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
CN113797330A (zh) * 2020-06-11 2021-12-17 三生国健药业（上海）股份有限公司 一种抗pd-1单克隆抗体液体制剂
CA3185871A1 (fr) * 2020-07-31 2022-02-03 Patrick S. Doyle Compositions comprenant des formes solides de polypeptides et methodes associees
EP4284834A1 (fr) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions d'anticorps anti-récepteur 1 de mort programmée (pd-1) et procédés d'obtention des compositions les contenant
CN113980093B (zh) * 2021-10-25 2024-07-26 河北工业大学 聚合物促进蛋白质类药物结晶的方法及应用
WO2024112623A1 (fr) * 2022-11-21 2024-05-30 Merck Sharp & Dohme Llc Procédés de préparation de cristaux d'anticorps anti-pd-1 humain et leurs procédés d'utilisation
WO2025085538A1 (fr) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Molécules de liaison à l'alarmine et traitement du cancer

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0365685B1 (fr) 1988-03-30 1995-01-18 Toray Industries, Inc. Préparation lyophilisée contenant un fragment Fab' marqué à la peroxydase de raifort d'un anticorps monoclonal anti interféron béta humain et du tréhalose ; kit EIA contenant cette préparation
EP0417193B1 (fr) 1988-05-27 1993-08-04 Centocor, Inc. Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
EP0853487B1 (fr) 1995-09-18 2000-07-05 Intracel Corporation Anticorps monoclonaux neutralisants diriges contre le virus syncytial respiratoire
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2352572C (fr) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Anticorps anti-interferon gamma humanises
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
EP1942114A3 (fr) 1999-03-11 2008-08-27 Schering Corporation "Cytokines de mammifères ; réactifs et procédés associés"
HK1044170B (en) 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2001030393A2 (fr) 1999-10-22 2001-05-03 Ludwig Institute For Cancer Research Procedes permettant de reduire les effets des cancers exprimant l'antigene a33 a l'aide d'immunoglobulines specifiques de l'antigene a33
US20050175986A1 (en) 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
EP1801123A3 (fr) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
WO2003009817A2 (fr) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
US20050276823A1 (en) 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
WO2004019861A2 (fr) 2002-08-28 2004-03-11 Pharmacia Corporation Preparation optimisee a ph stable d'anticorps modifie
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
JP4703566B2 (ja) 2003-05-14 2011-06-15 イムノゲン インコーポレーティッド 薬剤複合体組成物
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
CN1953768B (zh) 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2006096461A2 (fr) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps contre m-csf
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
RS51845B (sr) 2005-04-22 2012-02-29 Eli Lilly And Company Specifična tgf beta 1 antitela
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP5089582B2 (ja) 2005-06-07 2012-12-05 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー ＴＮＦαを阻害する安定な可溶性抗体
WO2006133486A1 (fr) 2005-06-14 2006-12-21 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Structures cristallines et modeles de complexes fc/recepteurs fc et utilisations de ces derniers
CN101287761A (zh) 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
WO2007016562A2 (fr) 2005-07-29 2007-02-08 Amgen Inc. Formulations inhibant l'agregation de proteines
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2006283194B9 (en) 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EA014025B1 (ru) 2005-09-12 2010-08-30 Новиммун С.А. Композиции антитела против cd3
WO2007036745A2 (fr) 2005-09-30 2007-04-05 Medimmune Limited Composition comprenant un anticorps anti-interleukine 13
EP1977763A4 (fr) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Préparation stabilisatrice contenant des anticorps
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
AU2007229554A1 (en) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
EP2044118A2 (fr) 2006-06-13 2009-04-08 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
CA2665567C (fr) 2006-10-06 2012-07-03 Amgen Inc. Formulations stables
CA2666492C (fr) 2006-10-20 2012-07-17 Douglas Rehder Formulations stables de polypeptide
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
AU2007328960B2 (en) 2006-12-05 2013-01-17 Crucell Holland B.V. Liquid anti-rabies antibody formulations
MX2009006471A (es) 2006-12-14 2009-06-26 Schering Corp Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
CA2672902C (fr) 2006-12-21 2012-11-27 Amgen Inc. Formulations
EP2114451A2 (fr) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Préparations d'anticorps ant-il-13 et leurs utilisations
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
ES2707815T3 (es) 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009002521A2 (fr) 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
WO2009114040A2 (fr) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2225275A4 (fr) 2007-11-28 2013-04-03 Medimmune Llc Formulation de protéine
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20110014203A1 (en) 2007-12-28 2011-01-20 Fredrik Nilsson Formulation
SG10201402265YA (en) 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
EP2242773B1 (fr) 2008-02-11 2017-06-14 Cure Tech Ltd. Anticorps monoclonaux pour le traitement de tumeurs
WO2009120684A1 (fr) 2008-03-25 2009-10-01 Medimmune, Llc Formulation d’anticorps
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
EP2307050A4 (fr) 2008-07-04 2012-07-25 Ono Pharmaceutical Co Utilisation d un marqueur d efficacité destiné à optimiser l efficacité thérapeutique d un anticorps pd-1 anti-humain sur les cancers
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
TR201802935T4 (tr) 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
EP2362767B1 (fr) 2008-10-29 2017-12-06 Ablynx N.V. Formulations de molécules de liaison d'antigène monodomaines
WO2010062372A2 (fr) 2008-11-03 2010-06-03 President And Fellows Of Harvard College Procédés de modulation de nf-kb mettant en oeuvre des gibbérellines
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
WO2010069858A1 (fr) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
EP2230312A1 (fr) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Composé de sonde pour détecter et isoler les enzymes et supports et procédés d'utilisation associés
RU2560701C2 (ru) 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
US20120183531A1 (en) 2009-07-14 2012-07-19 Biogen Idee Ma Inc Methods for Inhibiting Yellow Color Formation in a Composition
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (fr) 2009-08-31 2011-03-03 三洋化成工業株式会社 Stabilisateur de solution aqueuse de protéines, solution aqueuse de protéines et détergent liquide contenant tous deux le stabilisateur, et méthode de stabilisation de protéines utilisant le stabilisateur
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
WO2011028962A1 (fr) 2009-09-04 2011-03-10 Xoma Technology Ltd. Coformulations d’anticorps
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
DK2478005T3 (en) 2009-09-15 2015-02-16 Ajinomoto Althea Inc Protein a crystals and cross bound crystals and methods of use thereof
PE20121646A1 (es) 2009-11-04 2012-12-02 Merck Sharp & Dohme Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
AU2010338305A1 (en) 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
US20120294866A1 (en) 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
US8415507B2 (en) 2010-02-03 2013-04-09 Laurus Labs Private Limited Pterostilbene cocrystals
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (fr) 2010-07-26 2012-02-09 Schering Corporation Bio-essais pour la détermination de la modulation de pd-1
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
CA2830806C (fr) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Formulations stables d'anticorps diriges contre le recepteur humain pd-1 de la mort programmee et traitements associes
BR112013025845A2 (pt) 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013012022A1 (fr) 2011-07-19 2013-01-24 中外製薬株式会社 Préparation à teneur en protéines stable renfermant de l'argininamide ou un composé analogue correspondant
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX363734B (es) 2011-10-27 2019-03-29 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
CA2869359C (fr) 2012-04-03 2021-03-23 University Court Of The University Of St Andrews Imagerie haute resolution de volumes etendus
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2846830A1 (fr) 2012-05-11 2015-03-18 Novartis AG Procédés de cristallisation pour la purification d'anticorps monoclonaux
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US20140227250A1 (en) 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
US20150307606A1 (en) 2012-12-13 2015-10-29 Ashwin Basarkar Lyophilized spherical pellets of anti-il-23 antibodies
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
MX385713B (es) 2013-03-13 2025-03-18 Seagen Inc Ciclodextrina y formulaciones de conjugados anticuerpo-fármaco.
EP2981821B2 (fr) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Test immunohistochimique pour détecter l'expression du ligand de mort programmée 1 (pd-l1) dans un tissu tumoral
WO2015011199A1 (fr) 2013-07-23 2015-01-29 Novaliq Gmbh Compositions d'anticorps stabilisées
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
EP3057612B1 (fr) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
KR20170052569A (ko) 2014-07-18 2017-05-12 어드박시스, 인크. 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
MY198017A (en) 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
WO2016035006A1 (fr) 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Nouveaux analogues de nucléotides, procédé de préparation de sofosbuvir et de ses analogues, nouvelles formes de sofosbuvir de dispersion solide de sofosbuvir
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
EP3237000A1 (fr) 2014-12-23 2017-11-01 Pfizer Inc Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト， インコーポレイテッド 癌免疫療法のための組成物及び方法
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016153839A1 (fr) 2015-03-20 2016-09-29 Merck Sharp & Dohme Corp. Combinaison d'un antagoniste de pd-1 et de vorinostat dans le traitement du cancer
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
ES2861352T3 (es) 2015-04-28 2021-10-06 Bristol Myers Squibb Co Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017009813A1 (fr) * 2015-07-16 2017-01-19 Laurus Labs Private Limited Nouveaux co-cristaux de caféine et leur formes polymorphes
CA2993177A1 (fr) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Anticorps therapeutiques qui se lient a lag3
JP2018526989A (ja) 2015-08-07 2018-09-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
WO2017030823A2 (fr) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anticorps anti-tigit
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
RU2731418C2 (ru) 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
KR20180068990A (ko) 2015-10-01 2018-06-22 포텐자 테라퓨틱스, 인코포레이티드 항-tigit 항체-결합 단백질 및 이의 사용 방법
SG10201912943RA (en) 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EP3394099A4 (fr) 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-il-10 modifiés
EP3405490B1 (fr) 2016-01-21 2021-10-20 Pfizer Inc. Anticorps mono et bispécifiques contre le variant iii du récepteur du facteur de croissance épidermique et contre le cd3, et leurs utilisations
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US10421811B2 (en) 2016-04-25 2019-09-24 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies
EP3848393A1 (fr) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Molécules d'anticorps pour le traitement du cancer
CA3026151A1 (fr) 2016-06-14 2017-12-21 Xencor, Inc. Anticorps inhibiteurs de points de controle bispecifiques
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
US20200131251A1 (en) 2016-12-23 2020-04-30 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN110366429B (zh) 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
IL269026B2 (en) 2017-03-31 2024-12-01 Bristol Myers Squibb Co Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US20200354453A1 (en) 2017-05-02 2020-11-12 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CA3060695A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-recepteur de mort programmee 1 (pd-1) et leurs procedes d'utilisation
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
CN111107873A (zh) 2017-09-05 2020-05-05 默沙东公司 用于降低生物制剂粘度的化合物
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
JP7399382B2 (ja) 2018-07-30 2023-12-18 武田薬品工業株式会社 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
AU2019374748A1 (en) 2018-11-05 2021-05-27 Merck Sharp & Dohme Llc Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer
WO2020097141A1 (fr) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN114787191A (zh) 2019-12-09 2022-07-22 基因泰克公司 抗pd-l1抗体制剂
MX2023003414A (es) 2020-09-24 2023-04-14 Merck Sharp & Dohme Llc Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y metodos de uso de las mismas.
WO2022146947A1 (fr) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3873941A4 (fr) 2022-07-27
KR102876292B1 (ko) 2025-10-28
JP2022512840A (ja) 2022-02-07
WO2020092233A1 (fr) 2020-05-07
CN113015748B (zh) 2025-12-12
CA3116592A1 (fr) 2020-05-07
EP3873941A1 (fr) 2021-09-08
CN113015748A (zh) 2021-06-22
JP7475341B2 (ja) 2024-04-26
US20210317215A1 (en) 2021-10-14
AU2019369222A1 (en) 2021-05-27
CN120842406A (zh) 2025-10-28
MX2021004928A (es) 2021-06-08
KR20210084561A (ko) 2021-07-07
US12576159B2 (en) 2026-03-17
BR112021008122A8 (pt) 2023-01-31
BR112021008122A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA52091A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3935155A4 (fr) Polypeptides effecteurs crispr-cas et procédés d'utilisation associés
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
EP3873939A4 (fr) Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation
EP3826641A4 (fr) Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3740186A4 (fr) Dosette de produit d'hygiène et ses procédés d'utilisation
MA56455A (fr) Auto-injecteur et procédés d'utilisation associés
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3830128A4 (fr) Anticorps anti-mica/b qui bloquent l'élimination de mica/b et procédés d'utilisation
MA51207A (fr) Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation
MA51453A (fr) Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
EP3768298A4 (fr) Anticorps anti-pd-l2 humains et leurs procédés d'utilisation